Three months’ treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

ABSTRACT Treatment with _α_1-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the

hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536

men with LUTS who were treated with alfuzosin (10 or 15 mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound

measurements at baseline and 3 months. Total prostate volume increased by 0.4 ml from baseline in placebo patients but decreased by −0.25 ml in the combined alfuzosin groups. Percentage

change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms;

percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither

total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by

a measurable change in prostate volume after 3 months’ treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment. Access through your institution Buy

or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online

access $259.00 per year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS

CLINICAL SIGNIFICANCE OF PROSTATE VOLUME AND TESTOSTERONE REDUCTION ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY Article Open

access 02 November 2022 COMPARATIVE EFFICACY AND SAFETY OF ALPHA-BLOCKERS AS MONOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Article Open access

15 May 2024 MIRABEGRON IMPROVES ERECTILE FUNCTION IN MEN WITH OVERACTIVE BLADDER AND ERECTILE DYSFUNCTION: A 12-WEEK PILOT STUDY Article 02 July 2021 REFERENCES * Algaba F . Pathophysiology

of benign prostatic hyperplasia. _Eur Urol_ 1994; 25 (suppl 1): 3–5. Article  Google Scholar  * Medina JJ, Parra RO, Moore RG . Benign prostatic hyperplasia (the aging prostate). _Med Clin

North Am_ 1999; 83: 1213–1229. Article  CAS  Google Scholar  * Akduman B, Crawford ED . Terazosin, doxazosin, and prazosin: current clinical experience. _Urology_ 2001; 58 (suppl 6A): 49–54.

Article  CAS  Google Scholar  * Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N . _α_1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without

affecting cell proliferation in patients with benign prostatic hyperplasia. _J Urol_ 1999; 161: 2002–2008. Article  CAS  Google Scholar  * Kyprianou N, Chon J, Benning CM . Effects of

alpha1-adrenoceptor (_α_1-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. _Prostate Suppl_ 2000; 9: 42–46. Article  CAS 

Google Scholar  * Roehrborn CG, for the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic

hyperplasia: a randomized, placebo-controlled trial. _Urology_ 2001; 58: 953–959. Article  CAS  Google Scholar  * Terris MK, Stamey TA . Determination of prostate volume by transrectal

ultrasound. _J Urol_ 1991; 145: 984–987. Article  CAS  Google Scholar  * Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC . Induction of prostate apoptosis by doxazosin in benign

prostatic hyperplasia. _J Urol_ 1998; 159: 1810–1815. Article  CAS  Google Scholar  * McKeage K, Plosker GL . Alfuzosin: a review of the therapeutic use of the prolonged-release formulation

given once daily in the management of benign prostatic hyperplasia. _Drugs_ 2002; 62: 633–653. Article  CAS  Google Scholar  * Ahtoy P, Chrétien P, Dupain T, Rauch C, Rouchouse A, Delfolie A

. Alfuzosin, an _α_1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. _Int J Clin Pharmacol Ther_ 2002;

40: 289–294. Article  CAS  Google Scholar  * Fulton B, Wagstaff AJ, Sorkin EM . Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign

prostatic hyperplasia. _Drugs_ 1995; 49: 295–320. Article  CAS  Google Scholar  * Taguchi K, Schäfers RF, Michel MC . Radioreceptor assay analysis of tamsulosin and terazosin

pharmacokinetics. _Br J Clin Pharmacol_ 1998; 45: 49–55. Article  CAS  Google Scholar  * Kyprianou N, Benning CM . Suppression of human prostate cancer cell growth by _α_1-adrenoceptor

antagonists doxazosin and terazosin _via_ induction of apoptosis. _Cancer Res_ 2000; 60: 4550–4555. PubMed  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS The ALFUS study was

sponsored by Sanofi-Synthelabo. Dr Roehrborn was funded investigator in the ALFUS trial. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * The University of Texas Southwestern Medical Center,

Dallas, TX, USA C G Roehrborn Authors * C G Roehrborn View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to C G

Roehrborn. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Roehrborn, C. Three months’ treatment with the _α_1-blocker alfuzosin does not affect total or

transition zone volume of the prostate. _Prostate Cancer Prostatic Dis_ 9, 121–125 (2006). https://doi.org/10.1038/sj.pcan.4500849 Download citation * Received: 08 March 2005 * Revised: 04

October 2005 * Accepted: 04 October 2005 * Published: 09 May 2006 * Issue Date: 01 June 2006 * DOI: https://doi.org/10.1038/sj.pcan.4500849 SHARE THIS ARTICLE Anyone you share the following

link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature

SharedIt content-sharing initiative KEYWORDS * alfuzosin * _α_1-blocker * benign prostatic hyperplasia * apoptosis * prostate volume